title: Effects of NC-1300, a gastric proton pump inhibitor, on healing of acetic acid-induced gastric ulcers in rats.
abstract: Effects of NC-1300 (a gastric proton pump inhibitor) on healing of experimental chronic gastric ulcers induced in rats were studied. Gastric ulcers were induced by the submucosal injection of 20% acetic acid (0.03 ml) into the antral-oxyntic border of the anterior wall of male Donryu rats (260-280 g). The healing of acetic acid ulcers was delayed by the daily subcutaneous administration of indomethacin (1 mg/kg) for two or four weeks after ulceration. Aggravation of healed ulcers was evoked by subcutaneous administration of indomethacin (1 mg/kg) once daily for four weeks to rats with four-week-old ulcers. Oral administration of NC-1300 (10, 30, or 100 mg/kg) once daily for two or four weeks after ulceration dose-dependently accelerated both natural and delayed healing of acetic acid ulcers. When the period of administration was extended from two to four weeks, the ED50 values (the dose reducing the ulcerated area by 50%) were decreased from 36.5 to 13.5 mg/kg in natural healing and from 76.0 to 23.0 mg/kg in delayed healing. Aggravation of four-week-old ulcers by indomethacin was significantly prevented by daily administration of NC-1300 (30 or 100 mg/kg) for four weeks. Acetic acid ulcers that were healed with NC-1300 given for four weeks after ulceration remained healed for four to eight weeks after the cessation of drug administration. A single administration of NC-1300 to normal rats and repeated administration of NC-1300 to rats with acetic acid ulcers for four weeks after ulceration caused the same degree of inhibition of gastric acid secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Applied Pharmacology, Kyoto Pharmaceutical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Okabe
authors.forename: H
authors.initials: H
authors.lastname: Miyake
authors.forename: S
authors.initials: S
authors.lastname: Yamasaki
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000085:Acetates; D000284:Administration, Oral; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D007213:Indomethacin; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000085:Acetates; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; C048733:2-((2-dimethylaminobenzyl)sulfinyl)benzimidazole; D009853:Omeprazole; D007213:Indomethacin